2. Study to assess adverse events and change in disease activity in adult participants with advanced solid tumors receiving intravenous (IV) ABBV-400 as monotherapy and in combination with IV bevacizumab. ClinicalTrials.gov. Updated July 15, 2024. Accessed July 31, 2024.发布...
The study is also evaluating ABBV-400 with bevacizumab in pts with CRC.Clinical trial information: NCT05029882.Preliminary efficacy outcomes.CRC Dosing Cohorts1.6 mg/kg Q3W(n = 32)2.4 mg/kg Q3W(n = 40)3.0 mg/kg Q3W(n = 41)Confirmed ORR, n (%)06 (15)8 (20)CBR12, n (%)11 (...
说明For research use only. Not suitable for clinical or therapeutic use. 公司简介 武汉益普生物科技有限公司位于武汉市洪山区华中农业大学天惠生物科技孵化器。 益普生物涵括各类分子生物学实验,面向生物医药企业、高等院校、科研机构、医院及个人,为生物医药研发、生命科学和医学研究提供全方位生物学实验解决方案. ...
Not suitable for clinical or therapeutic use. Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have ...
Raghav, MD, MBBS, clinical medical director, Division of Ambulatory Treatment Centers (MDACC), and associate professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas ...
2. Study to assess adverse events and change in disease activity in adult participants with advanced solid tumors receiving intravenous (IV) ABBV-400 as monotherapy and in combination with IV bevacizumab. ClinicalTrials.gov. Updated July 15, 2024. Accessed July 31, 2024....
ABBV-400 has progressed through dose escalation, and dose expansion is currently ongoing in a Phase 1 FIH clinical study (NCT05029882).All authors were employees of AbbVie during this research. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie ...
(ORR); while the 3.0 mg/kg dose may provide higher response rates, the 2.4 mg/kg Q3W dosing regimen provides an optimal balance of safety and efficacy compared to 3.0 mg/kg Q3W.Conclusions:Population PK, E-R for efficacy and safety and RDI analyses and totality of clinical data supported...
Raghav, MD, MBBS, clinical medical director, Division of Ambulatory Treatment Centers (MDACC), and associate professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas...
A. VasilopoulosPrecision Medicine and Clinical Biomarker, Oncology, AbbVie Inc-Headquarters, North Chicago, IL, USAR.R. LiCompanion Diagnostic Strategy, AbbVie Inc-Headquarters, North Chicago, IL, USAK. FreiseOncology, AbbVie Inc-Headquarters, North Chicago, IL, USA...